It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

FDA approval of Filkri expands Accord’s G-CSF biosimilar portfolio, offering a short-acting option for neutropenia in cancer care.

Biocon aims for growth through new biosimilar launches and expanded insulin capacity, projecting significant revenue contributions from key products.

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for ...

But Amgen’s true success stems from putting people first. By creating an environment where innovation, inclusion and ...

A nine percent increase in 2024 helped propel Ohio State to ranking 12th in the nation in total research funding, and sixth for industrial research. Ohio State recorded nearly $1.6 billion in research ...

On January 28, Argus trimmed its price recommendation on CVS Health Corporation (NYSE:CVS) to $90 from $91. However, the firm maintained a Buy rating on the stock.

Amgen Balances Broad Growth With Manageable Risks in Latest Earnings Call ...

CVS Health Inc. (NYSE: CVS) on Thursday said it is taking additional steps to lower prescription drug costs by expanding access to biosimilar medications, announcing new formulary changes that will ...

Feb 5 (Reuters) - (This Feb 5 story has been corrected to fix Prolia's 2025 sales to $4.4 billion, not $1.05 billion, in paragraph 5) Sign up here. Its pharmacy benefit management unit, Caremark, will ...

CVS Health said on Thursday it would swap out Amgen and Eli Lilly's bone disease treatments for lower-cost alternatives in some of ‍its preferred drug lists, starting April 1. Its pharmacy benefit ...